Menu Back toBasics of Healthcare Reform for Lifesciences Professionals

DIA 2021 Global Annual Meeting

Basics of Healthcare Reform for Lifesciences Professionals

Session Chair(s)

Mitchell  Berger, JD, MPH, RAC

Mitchell Berger, JD, MPH, RAC

  • Public Health Advisor
  • HHS, United States
This forum provides an overview of healthcare reform basics for pharmaceutical industry staff amid the ongoing impact of COVID-19 and calls for health equity. Topics discussed include major US health care programs, pharmaceutical pricing and innovation models.
Learning Objective : Summarize major health care programs of interest to the pharmaceutical industry such as Medicare and Medicaid; Describe recent steps by federal and state governments to promote innovation; Discuss drug pricing and how ongoing health system delivery reform changes, such as value-based design and comparative effectiveness may impact the pharmaceutical industry.


Ed  Weisbart, MD, FAAFP

Potential Health Reform Approaches (e.g., Public Option, Medicare for All)

Ed Weisbart, MD, FAAFP

  • Chair, MO Chapter
  • Physicians for a National Health Program, United States
Barry  Berger, JD, MBA

Overview of Drug Pricing (US)

Barry Berger, JD, MBA

  • Retired
  • Former Professor of Regulatory Affairs, Temple University, United States
Rebecca  Yip, MS

CMS Innovation Models

Rebecca Yip, MS

  • Principal
  • Avalere Health, United States